UK markets closed

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.46+0.27 (+5.20%)
At close: 4:00PM EDT
5.45 -0.01 (-0.18%)
After hours: 05:29PM EDT
Currency in USD

Valuation measures

Market cap (intra-day) 5355.76M
Enterprise value 397.92M
Trailing P/E N/A
Forward P/E 1-3.46
PEG ratio (5-yr expected) 14.72
Price/sales (ttm)5.36
Price/book (mrq)2.72
Enterprise value/revenue 31.47
Enterprise value/EBITDA 7-1.58

Trading information

Stock price history

Beta (5Y monthly) 0.69
52-week change 3-22.77%
S&P500 52-week change 331.43%
52-week high 310.05
52-week low 34.28
50-day moving average 35.09
200-day moving average 36.85

Share statistics

Avg vol (3-month) 3712.45k
Avg vol (10-day) 3895.55k
Shares outstanding 565.16M
Implied shares outstanding 6N/A
Float 53.93M
% held by insiders 11.29%
% held by institutions 189.21%
Shares short (30 Aug 2021) 45.9M
Short ratio (30 Aug 2021) 48.27
Short % of float (30 Aug 2021) 49.16%
Short % of shares outstanding (30 Aug 2021) 49.05%
Shares short (prior month 29 Jul 2021) 46.99M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Jun 2021


Profit margin -96.67%
Operating margin (ttm)-97.12%

Management effectiveness

Return on assets (ttm)-10.02%
Return on equity (ttm)-67.66%

Income statement

Revenue (ttm)66.42M
Revenue per share (ttm)1.21
Quarterly revenue growth (yoy)-1.90%
Gross profit (ttm)100.36M
EBITDA -61.84M
Net income avi to common (ttm)-64.21M
Diluted EPS (ttm)-1.17
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)266.18M
Total cash per share (mrq)4.09
Total debt (mrq)23.32M
Total debt/equity (mrq)17.81
Current ratio (mrq)2.90
Book value per share (mrq)2.01

Cash flow statement

Operating cash flow (ttm)-100.24M
Levered free cash flow (ttm)-16.73M